Project Grant HT94252510569

Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $720K
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award of $480,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by Baylor College of Medicine in Houston, Texas to investigate "TARGETING CRYPTIC SPLICING-DERIVED NEOANTIGENS IN HNRNPM-DYSREGULATED TRIPLE-NEGATIVE BREAST CANCER". The project aims to transform healthcare for military service members, veterans, and the broader public through...
This $1,600,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Baylor College of Medicine focused on developing new synthetic lethal combination therapies targeting TopBP1 and the arachidonic acid pathway for breast cancer treatment. The three-year award, with an end date of February 28, 2027, will fund basic, translational, and clinical research aimed at advancing scientific understanding and...
The federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to support the research project "BCL-XL IN BREAST CANCER METASTASIS AND THERAPY" at Baylor College of Medicine in Houston, Texas. The award, with a performance period from August 1, 2024 to July 31, 2027, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...
Baylor College of Medicine will use a $1.56 million project grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through this four-year award, Baylor College of Medicine will investigate medical solutions for breast cancer through innovative and impactful research aimed at transforming health care for service members and the...
This federal Project Grant award of $2,239,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate the progression from ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer driven by the N-RAS gene. The research project aims to advance the understanding of this disease process with the potential to lead to improved diagnostic and treatment approaches. The award...
This $1,200,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to eliminate bone metastasis through a bone-targeting E-cadherin antibody nanogel. The 4-year award, effective from April 1, 2025 to March 31, 2028, aims to transform healthcare for military service members, veterans, and the broader public through innovative biomedical research. As a leading academic medical...
The Baylor College of Medicine will leverage spliceosome-targeted therapies to harness the immune system against metastatic breast cancer under a $800,000 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program, with the CFDA number 12.420, which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield injuries and...
This Defense Health Agency Project Grant award of $1,225,878.00 to Baylor College of Medicine, granted under the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420), is investigating the use of nebivolol, a beta-blocker medication, as a potential treatment for triple-negative breast cancer. The research project, which runs from January 1, 2024 to December 31, 2026, aims to advance scientific understanding and develop new treatment options for this...
This $1,200,000.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund Baylor College of Medicine to conduct research on precision glycocalyx editing of the metastatic bone microenvironment over a three-year period from September 15, 2023 to September 14, 2026. As a private non-profit university, Baylor College of Medicine has extensive experience managing federal grants and contracts for biomedical...
The federal Project Grant award of $1,496,576.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Baylor College of Medicine in Houston, Texas, aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational domains, will focus on innovative investigations across multiple medical...

This federal Project Grant award of $720,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate "Targeting Cryptic Splicing-Derived Neoantigens in HNRNPM-Dysregulated Triple-Negative Breast Cancer". The research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical research across diverse medical domains. Baylor College of Medicine, a prestigious private non-profit health sciences university, will conduct this 3-year research project from September 1, 2025 to August 31, 2028. The grant funding will enable Baylor to perform advanced, translational research into novel cancer immunotherapies targeting breast cancer, with the goal of developing more effective treatments.

Generated 8/5/25, 4:34 AM